My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 114

    1.

    Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD).

    McEwen LN, Bilik D, Johnson SL, Halter JB, Karter AJ, Mangione CM, Subramanian U, Waitzfelder B, Crosson JC, Herman WH.

    Diabetes Care. 2009 Jun;32(6):971-6. Epub 2009 Feb 19.PMID: 19228862 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Glycemic response to newly initiated diabetes therapies.

    Karter AJ, Moffet HH, Liu J, Parker MM, Ahmed AT, Go AS, Selby JV.

    Am J Manag Care. 2007 Nov;13(11):598-606.PMID: 17988185 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%.

    Pani LN, Nathan DM, Grant RW.

    Diabetes Care. 2008 Mar;31(3):386-90. Epub 2007 Dec 14.PMID: 18083790 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management.

    Grant R, Adams AS, Trinacty CM, Zhang F, Kleinman K, Soumerai SB, Meigs JB, Ross-Degnan D.

    Diabetes Care. 2007 Apr;30(4):807-12. Epub 2007 Jan 26.PMID: 17259469 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.

    Riedel AA, Heien H, Wogen J, Plauschinat CA.

    Pharmacotherapy. 2007 Aug;27(8):1102-10.PMID: 17655510 [PubMed - indexed for MEDLINE]Related articles

    6.

    Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.

    Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR.

    Diabetes Care. 2005 May;28(5):995-1000.PMID: 15855556 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program.

    Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA.

    J Manag Care Pharm. 2006 Jul-Aug;12(6):466-71.PMID: 16925454 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Nonadherence to insulin therapy in low-income, type 2 diabetic patients.

    Lerman I, Díaz JP, Ibarguengoitia ME, Pérez FJ, Villa AR, Velasco ML, Cruz RG, Rodrigo JA.

    Endocr Pract. 2009 Jan-Feb;15(1):41-6.PMID: 19211396 [PubMed - indexed for MEDLINE]Related articles

    9.

    Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.

    Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S.

    JAMA. 1997 Nov 26;278(20):1663-9. Erratum in: JAMA 1999 Jun 2;281(21):1989. PMID: 9388085 [PubMed - indexed for MEDLINE]Related articles

    10.

    Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.

    Jermendy G; Hungarian RECAP Group, Erdesz D, Nagy L, Yin D, Phatak H, Karve S, Engel S, Balkrishnan R.

    Health Qual Life Outcomes. 2008 Oct 31;6:88.PMID: 18976457 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.

    Riedel AA, Heien H, Wogen J, Plauschinat CA.

    Am J Manag Care. 2007 Aug;13(8):457-63.PMID: 17685826 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

    [No authors listed]

    Ann Intern Med. 1998 Feb 1;128(3):165-75.PMID: 9454524 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.

    Duckworth W, Marcelli M, Padden M, Kellick K, Duhancik T, Wilhardt M, Colgan K, Romie A.

    J Manag Care Pharm. 2003 May-Jun;9(3):256-62.PMID: 14613469 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

    Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.

    Clin Ther. 2003 Apr;25(4):1074-95.PMID: 12809958 [PubMed - indexed for MEDLINE]Related articles

    15.

    Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.

    Yurgin N, Secnik K, Lage MJ.

    Clin Ther. 2007 Feb;29(2):316-25.PMID: 17472823 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus.

    Yki-Järvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Salo S, Seppälä P, Tulokas T, Viikari J, Taskinen MR.

    J Clin Endocrinol Metab. 1997 Dec;82(12):4037-43.PMID: 9398709 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Medication adherence and racial differences in A1C control.

    Adams AS, Trinacty CM, Zhang F, Kleinman K, Grant RW, Meigs JB, Soumerai SB, Ross-Degnan D.

    Diabetes Care. 2008 May;31(5):916-21. Epub 2008 Jan 30.PMID: 18235050 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Racial and ethnic disparities in the control of cardiovascular disease risk factors in Southwest American veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study.

    Wendel CS, Shah JH, Duckworth WC, Hoffman RM, Mohler MJ, Murata GH.

    BMC Health Serv Res. 2006 May 23;6:58.PMID: 16716235 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

    Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

    Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

    20.

    The utility of insulin glargine in the treatment of diabetes mellitus.

    Stroup J, Kane MP, Busch RS, Bakst G, Hamilton RA.

    Pharmacotherapy. 2004 Jun;24(6):736-42.PMID: 15222663 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity